Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504016 | 0.87 | MAPK14 (0.81) | MAPK14PTGS2 | |
| SCHEMBL6280887 | 0.86 | MAPK14 (1.00) | MAPK14PTGS2PTGS1 | |
| SCHEMBL6280814 | 0.85 | MAPK14 (0.55) | MAPK14PTGS2 | |
| SCHEMBL7844433 | 0.84 | PTGS2 (0.80) | MAPK14PTGS2 | |
| SCHEMBL6503233 | 0.83 | PTGS2 (0.78) | MAPK14PTGS2PTGS1 | |
| SCHEMBL7841916 | 0.83 | PTGS2 (1.00) | MAPK14PTGS2PTGS1 | |
| SCHEMBL6508524 | 0.83 | PTGS2 (1.00) | MAPK14PTGS2PTGS1 | |
| SCHEMBL7843526 | 0.82 | PTGS2 (0.78) | MAPK14PTGS2PTGS1 | |
| SCHEMBL6503358 | 0.82 | PTGS2 (0.78) | MAPK14PTGS2PTGS1 | |
| SCHEMBL6505328 | 0.81 | MAPK14 (0.51) | MAPK14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885PTGS2 57/4885PTGS1 9/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | MAPK14 29/4885PTGS2 109/4885PTGS1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.